SCHEMBL24252645

SCHEMBL24252645

COc1cc(F)c(B(O)O)cc1-c1ccc2c(N)nnc(C)c2c1

nearest known ligand 0.34

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
FYN P06241 6/20 0.34
DHFR P00374 4/20 0.34
ALOX5AP P20292 2/20 0.33
FEN1 P39748 2/20 0.33
PRKCZ Q05513 1/20 0.33
MAP4K4 O95819 1/20 0.33
CHEK2 O96017 1/20 0.32
LRRK2 Q5S007 1/20 0.32
KIT P10721 1/20 0.31
KDM4E B2RXH2 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
PIK3CA P42336 1/20 0.31
PDE10A Q9Y233 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30451530 1.00 FYN (0.34) FYNDHFRALOX5APFEN1PRKCZ
SCHEMBL26771077 0.93 DHFR (0.33) FYNDHFRALOX5APFEN1PRKCZ
SCHEMBL24252646 0.88 DHFR (0.36) FYNDHFRMAP4K4CHEK2KIT
SCHEMBL30451987 0.86 PLAU (0.36) FYNDHFRMAP4K4CHEK2PDE10A
SCHEMBL24252368 0.86 PLAU (0.36) FYNDHFRMAP4K4CHEK2PDE10A
SCHEMBL24252696 0.86 DHFR (0.34) FYNDHFRMAP4K4CHEK2
SCHEMBL30453223 0.86 DHFR (0.34) FYNDHFRMAP4K4CHEK2
SCHEMBL24252695 0.86 SOS1 (0.35) FYNDHFRALOX5APFEN1MAP4K4
SCHEMBL30453116 0.85 SCN9A (0.35) FYNDHFRALOX5APFEN1MAP4K4
SCHEMBL24252657 0.85 SCN9A (0.35) FYNDHFRALOX5APFEN1MAP4K4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON INC (US) 2026-03-12 US disclosed
US-12509474-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2025-12-30 US disclosed
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2024-04-04 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
US-11814404-B2 Inhibitors of complement factors and uses thereof ANNEXON, INC. (US) 2023-11-14 US disclosed
EP-4185592-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF Annexon, Inc. (US) 2023-05-31 EP disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF ANNEXON, INC. 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240109920-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 FYN 1558/4885DHFR 1380/4885ALOX5AP 246/4885
US-20220048930-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFB, CFH, C9 FYN 1558/4885DHFR 1380/4885ALOX5AP 246/4885
US-11814404-B2 Inhibitors of complement factors and uses thereof CFB, CFH, C9 FYN 1558/4885DHFR 1380/4885ALOX5AP 246/4885
US-12509474-B2 Inhibitors of complement factors and uses thereof SSB, UACA, CFH FYN 2329/4885DHFR 4573/4885ALOX5AP 351/4885
US-20260070932-A1 INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF CFH, CFB, C5 FYN 996/4885DHFR 3196/4885ALOX5AP 167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.